PHCNA’s Tia Harmon highlighted technologies for real-time metabolic monitoring that give manufacturers earlier insight into cell behavior during complex cell and gene therapy (CGT) workflows. The piece outlines how continuous monitoring helps detect deviations, optimize harvest timing and enable corrective interventions to improve batch consistency. Real-time sensors for metabolites and cell state markers promise to reduce batch failures and accelerate process development. Adoption of these platforms could shorten timelines for IND-enabling studies and improve comparability between clinical and commercial manufacturing runs, according to industry practitioners cited in the coverage.